Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats

International Journal of Molecular Medicine

Volumn 33, Issue 1, 2014, Pages 68-76

  Arima, Shiho ^a   Uto, Hirofumi ^a   Ibusuki, Rie ^a   Kumamoto, Ryo ^a   Tanoue, Shirou ^a   Mawatari, Seiichi ^a   Oda, Kohei ^a   Numata, Masatsugu ^a   Fujita, Hiroshi ^a   Oketani, Makoto ^a   Ido, Akio ^a   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatic fibrosis; Hypertension; Liver injury; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; AMINO ACID; CHOLINE; GLUCOSE; HEME OXYGENASE 1; INTERLEUKIN 10; MESSENGER RNA; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; DISEASE EXACERBATION; DISEASE SEVERITY; FATTY LIVER; FEEDING; GLUCOSE BLOOD LEVEL; HYPERTENSION; LIVER FIBROSIS; LIVER INJURY; MALE; METABOLIC PARAMETERS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SALT INTAKE; SODIUM RESTRICTION; STAINING; SYSTOLIC BLOOD PRESSURE;

ALANINE TRANSAMINASE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLINE DEFICIENCY; DIET; FATTY LIVER; HEME OXYGENASE (DECYCLIZING); HYPERTENSION; INTERLEUKIN-10; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, INBRED SHR; RISK FACTORS; RNA, MESSENGER;

EID: 84892698334     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1544     Document Type: Article

References (43)

1. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51: 1972-1978, 2010.
2. Yasui K, Hashimoto E, Tokushige K, et al: Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res 42: 767-773, 2012.
3. Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121, 2005.
4. Hamaguchi M, Kojima T, Takeda N, et al: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722-728, 2005.
5. López-Suárez A, Guerrero JM, Elvira-González J, Beltrán-Robles M, Cañas-Hormigo F and Bascuñana-Quirell A: Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol 23: 1011-1017, 2011.
6. Dixon JB, Bhathal PS and O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91-100, 2001.
7. Nakae D, Yoshiji H, Mizumoto Y, et al: High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 52: 5042-5045, 1992.
8. Matsui H, Ando K, Kawarazaki H, et al: Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52: 287-294, 2008.
9. Hsu CT: Ultrastructural changes in liver damage induced by carbon tetrachloride in spontaneously hypertensive rats and Wistar-Kyoto rats. J Auton Nerv Syst 70: 79-83, 1998.
10. Ikuta T, Kanno K, Arihiro K, et al: Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. Hepatol Res 42: 310-320, 2012.
11. Svoboda DS and Kawaja MD: Changes in hepatic protein expression in spontaneously hypertensive rats suggest early stages of non-alcoholic fatty liver disease. J Proteomics 75: 1752-1763, 2012.
12. Amarapurkar DN, Hashimoto E, Laurentius LA, et al: Howcommon is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793, 2007.
13. Lewis JR and Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55: 560-578, 2010.
14. Kojima S, Watanabe N, Numata M, Ogawa T and Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 38: 954-961, 2003.
15. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D and Dina L: Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 17: 255-260, 2008.
16. Jimba S, Nakagami T, Takahashi M, et al: Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22: 1141-1145, 2005.
17. Matrougui K, Abd Elmageed Z, Kassan M, et al: Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol 178: 434-441, 2011.
18. Kassan M, Galan M, Partyka M, Trebak M and Matrougui K: Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 31: 2534-2542, 2011.
19. Cintra DE, Pauli JR, Araújo EP, et al: Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 48: 628-637, 2008.
20. Shen XD, Ke B, Zhai Y, et al: Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant 5: 1793-1800, 2005.
21. Yu HP, Choudhry MA, Shimizu T, et al: Mechanism of the salutary effects of flutamide on intestinal myeloperoxidase activity following trauma-hemorrhage: up-regulation of estrogen receptor-β-dependent HO-1. J Leukoc Biol 79: 277-284, 2006.
22. Liu FC, Hwang TL, Lau YT and Yu HP: Mechanism of salutary effects of astringinin on rodent hepatic injury following trauma-hemorrhage: Akt-dependent hemeoxygenase-1 signaling pathways. PLoS One 6: e25907, 2011.
23. Devey L, Mohr E, Bellamy C, et al: c-Jun terminal kinase-2 gene deleted mice overexpress hemeoxygenase-1 and are protected from hepatic ischemia reperfusion injury. Transplantation 88: 308-316, 2009.
24. Yu HP, Yang SC, Lau YT and Hwang TL: Role of Akt-dependent up-regulation of hemeoxygenase-1 in resveratrol-mediated attenuation of hepatic injury after trauma hemorrhage. Surgery 148: 103-109, 2010.
25. Elmarakby AA, Faulkner J, Baban B and Sullivan JC: Induction of hemeoxygenase-1 reduces renal oxidative stress and inflammation in diabetic spontaneously hypertensive rats. Int J Hypertens 2012: 957235, 2012.
26. Hou HS, Liao CL, Sytwu HK, et al: Deficiency of interleukin-15 enhances susceptibility to acetaminophen-induced liver injury in mice. PLoS One 7: e44880, 2012.
27. Zhou YC, Chen S, Cao JJ, Chen SY, Xie YF and Niu QX: Adenovirus-mediated viral interleukin-10 gene transfer prevents concanavalin A-induced liver injury. Dig Liver Dis 44: 398-405, 2012.
28. Zhang LJ, Zheng WD, Shi MN and Wang XZ: Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver. World J Gastroenterol 12: 1918-1923, 2006.
29. Lee TS and Chau LY: Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat Med 8: 240-246, 2002.
30. Gunnett CA, Heistad DD and Faraci FM: Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes 51: 1931-1937, 2002.
31. Zhang LJ, Zheng WD, Chen YX, et al: Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 54: 2092-2098, 2007.
32. Hamaguchi M, Kojima T, Takeda N, et al: Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13: 1579-1584, 2007.
33. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52, 2005.
34. Donati G, Stagni B, Piscaglia F, et al: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53: 1020-1023, 2004.
35. Pollare T, Lithell H and Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 39: 167-174, 1990.
36. Raitakari OT, Porkka KV, Rönnemaa T, et al: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The cardiovascular risk in young finns study. Diabetologia 38: 1042-1050, 1995.
37. Allemann Y, Horber FF, Colombo M, et al: Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet 341: 327-331, 1993.
38. Ogihara T, Asano T, Ando K, et al: High-salt diet enhances insulin signaling and induces insulin resistance in Dahl saltsensitive rats. Hypertension 40: 83-89, 2002.
39. Ogihara T, Asano T and Fujita T: Contribution of salt intake to insulin resistance associated with hypertension. Life Sci 73: 509-523, 2003.
40. Petta S, Macaluso FS, Barcellona MR, et al: Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One 7: e51165, 2012.
41. Aithal GP, Thomas JA, Kaye PV, et al: Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176-1184, 2008.
42. Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: old questions and new insights. Science 332: 1519-1523, 2011.
43. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.